SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Brown JM. Evidence for acutely hypoxic cells in mouse tumours and a possible mechanism of reoxygenation. Br J Radiol. 1979; 52: 650656.
  • 2
    Chaplin DJ, Horsman MR, Aoki DS. Nicotinamide, fluosol DA and carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br J Cancer. 1991; 63: 109113.
  • 3
    Kjellen E, Joiner MC, Collier JM, Johns H, Rojas A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother Oncol. 1991; 22: 8191.
  • 4
    Rojas A, Hirst VK, Calvert AS, Johns H. Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy. Int J Radiat Oncol Biol Phys. 1996; 34: 357365.
  • 5
    Rojas A, Vojnovic B, Johns H, et al. Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated X-ray schedules. Radiother Oncol. 1996; 39: 5364.
  • 6
    Rojas A. ARCON: accelerated radiotherapy with carbogen and nicotinamide. Br J Radiol. 1992; 24: 174178.
  • 7
    Overgaard J. Modification of hypoxia—from Gottwald Schwarz to nicotinamide. Have we learned the lesson? In: KogelnikHD, editor. Progress in radio-oncology. Bologna: Monduzzi Editore, 1995: 469475.
  • 8
    Hoskin PJ, Saunders MI, Phillips H, et al. Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br J Cancer. 1997; 76: 260263.
  • 9
    Kaanders JH, Pop LA, Marres HA, et al. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol. 1998; 48: 115122.
  • 10
    Saunders MI, Hoskin PJ, Pigott K, et al. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study. Radiother Oncol. 1997; 45: 159166.
  • 11
    Kaanders JH, Pop LA, Marres HA, et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002; 52: 769778.
  • 12
    Dische S. What have we learnt from hyperbaric oxygen? Radiother Oncol. 1991; 20: 7174.
  • 13
    Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol. 1986; 7: 299310.
  • 14
    Gospodarowicz MK, Rider W, Keen CW, et al. Bladder cancer: long term follow-up results of patients treated with radical radiation. Clin Oncol. 1991; 3: 155161.
  • 15
    Hoskin PJ, Stratford MRL, Saunders MI, Hall DW, Dennis MF, Rojas A. Administration of nicotinamide during CHART: pharmacokinetics, dose escalation, and clinical toxicity. Int J Radiat Oncol Biol Phys. 1995; 32: 11111119.
  • 16
    Stratford MRL, Dennis MF, Hoskin PJ, Saunders MI, Hodgkiss RJ, Rojas A. Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy. Acta Oncol. 1996; 35: 213219.
  • 17
    Dische S, Rojas A, Rugg T, Hong A, Michael BD. Carbogen breathing: a system for use in man. Br J Radiol. 1992; 65: 8790.
  • 18
    Powell ME, Collingridge DR, Saunders MI, Hoskin PJ, Hill SA, Chaplin DJ. Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiother Oncol. 1999; 50: 167171.
  • 19
    Dische S, Warburton MF, Jones D, Lartigau E. The recording of morbidity related to radiotherapy. Radiother Oncol. 1989; 16: 103108.
  • 20
    Borgaonkar S, Jain A, Bollina P, et al. Radical radiotherapy and salvage cystectomy as the primary management of transitional cell carcinoma of the bladder. Results following the introduction of a CT planning technique. Clin Oncol. 2002; 14: 141147.
  • 21
    Lynch WJ, Jenkins BJ, Fowler CG, Hope-Stone HF, Blandy JP. The quality of life after radical radiotherapy for bladder cancer. Br J Urol. 1992; 70: 519521.
  • 22
    Edsmyr F, Andersson L, Esposti PL, Littbrand B, Nilsson B. Irradiation therapy with multiple small fractions per day in urinary bladder cancer. Radiother Oncol. 1985; 4: 197203.
  • 23
    Jahnson S, Pedersen J, Wesman G. Bladder carcinoma a 20-year review of radical irradiation therapy. Radiother Oncol. 1991; 22: 111117.
  • 24
    Perez CA, Brady LW. Overview. In: PerezCA, BradyLW, editors. Principles and practice of radiation oncology. Philadelphia: Lippincott, 1992: 163.
  • 25
    Mornex F, Pavy JJ, Denekamp J, Bolla M. Scoring system of late effects of radiation on normal tissues: the SOMA-LENT scale. Cancer Radiother. 1997; 1: 622668.
  • 26
    Maciewjewski B, Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol. 1991; 21: 163170.
  • 27
    de Neve W, Lybeert MLM, Goor C, Crommelin MA, Ribot JG. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol. 1995; 36: 183188.
  • 28
    Moonen L, van de Voet H, Horenblas S, Bartelink H. A feasibility study of accelerated fractionation in radiotherapy of carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys. 1997; 37: 537542.